Literature DB >> 11769739

Late onset white matter disease in peroxisome biogenesis disorder.

P G Barth1, J Gootjes, H Bode, P Vreken, C B Majoie, R J Wanders.   

Abstract

OBJECTIVE: To report late onset cerebral white matter disease as a distinctive phenotype in peroxisome biogenesis disorder (PBD).
BACKGROUND: There is phenotypic and genetic overlap among the PBD known as Zellweger syndrome (ZS), infantile Refsum disease (IRD), and neonatal adrenoleukodystrophy (NALD). Distinctive external features are variable among these three disorders, and neurologic deficit has its onset at birth or in infancy. In a structured follow-up cohort of 25 patients with PBD, not including ZS, three patients had an unusual pattern of cerebral white matter disease with onset past the age of 1, not conforming to any of the classic PBD phenotypes.
METHODS: Clinical phenotyping and follow-up, peroxisomal biochemical determinations in body fluids and fibroblasts, identification of affected PEX gene by genetic complementation in fibroblasts, and MRI studies.
RESULTS: Two unrelated patients with PBD without distinctive external features had normal neurodevelopmental milestones during their first year, followed by rapid deterioration including severe hypotonic pareses, seizures, retinopathy, and deafness. A third patient initially diagnosed with IRD developed cerebral white matter degeneration in the third year of life, complicating the original diagnosis. MRI in all three patients showed cerebral demyelination with sparing of subcortical fibers and pronounced central cerebellar demyelination.
CONCLUSIONS: Late-onset cerebral white matter disease may occur in PBD, either following IRD or following normal early development and in the absence of distinctive external features. Peroxisome biogenesis disorder should be included in the differential diagnosis of post-infantile onset of cerebral white matter disease

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11769739     DOI: 10.1212/wnl.57.11.1949

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  7 in total

1.  Mild Zellweger syndrome due to a novel PEX6 mutation: correlation between clinical phenotype and in silico prediction of variant pathogenicity.

Authors:  Małgorzata Rydzanicz; Teresa Joanna Stradomska; Elżbieta Jurkiewicz; Ewa Jamroz; Piotr Gasperowicz; Grażyna Kostrzewa; Rafał Płoski; Anna Tylki-Szymańska
Journal:  J Appl Genet       Date:  2017-10-18       Impact factor: 3.240

Review 2.  Tools for diagnosis of leukodystrophies and other disorders presenting with white matter disease.

Authors:  Adeline Vanderver
Journal:  Curr Neurol Neurosci Rep       Date:  2005-03       Impact factor: 5.081

3.  Peroxisomal biogenesis disorder: comparison of conventional MR imaging with diffusion-weighted and diffusion-tensor imaging findings.

Authors:  Birgitta S M ter Rahe; Charles B L M Majoie; Erik M Akkerman; Gerard J den Heeten; Bwee T Poll-The; Peter G Barth
Journal:  AJNR Am J Neuroradiol       Date:  2004 Jun-Jul       Impact factor: 3.825

4.  Cerebral MRI as a valuable diagnostic tool in Zellweger spectrum patients.

Authors:  S Weller; H Rosewich; J Gärtner
Journal:  J Inherit Metab Dis       Date:  2008-04-14       Impact factor: 4.982

5.  X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up and management.

Authors:  Marc Engelen; Stephan Kemp; Marianne de Visser; Björn M van Geel; Ronald J A Wanders; Patrick Aubourg; Bwee Tien Poll-The
Journal:  Orphanet J Rare Dis       Date:  2012-08-13       Impact factor: 4.123

Review 6.  Zellweger spectrum disorders: clinical overview and management approach.

Authors:  Femke C C Klouwer; Kevin Berendse; Sacha Ferdinandusse; Ronald J A Wanders; Marc Engelen; Bwee Tien Poll-The
Journal:  Orphanet J Rare Dis       Date:  2015-12-01       Impact factor: 4.123

Review 7.  The Key Role of Peroxisomes in Follicular Growth, Oocyte Maturation, Ovulation, and Steroid Biosynthesis.

Authors:  Shan Wang; HaoXuan Yang; YongLun Fu; XiaoMing Teng; ChiChiu Wang; WenMing Xu
Journal:  Oxid Med Cell Longev       Date:  2022-02-03       Impact factor: 6.543

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.